Myriad Genetics up 27% on new insurance coverage for GeneSight test

Myriad Genetics (MYGN +27.1%) is up on light volume in early trade in response to a positive coverage decision at UnitedHealthcare for pharmacogenetic testing with multigene panels, including MYGN’s GeneSight Psychotropic test, for patients with major depressive disorder who have failed at least one prior line of therapy.

https://seekingalpha.com/news/3485380-myriad-genetics-27-percent-new-insurance-coverage-genesight-test